{"groups":[{"description":"Zanubrutinib (160 milligrams \\[mg\\]) administered orally twice daily (BID) until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"FG000","title":"Zanubrutinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"49"}],"type":"Primary and secondary objectives were met and remaining participants transferred to LTE by sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"86"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"86"}],"comment":"Safety Analysis Set","type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"86"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study was conducted at 14 study centers in China; 13 study centers enrolled participants. Once the primary and secondary objectives were met and the analysis was complete, sponsor ended the study on 08 September 2020 and transferred all participants remaining on treatment to long term extension study."}